NCT03032484View on ClinicalTrials.gov

TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 18, 2017

Primary Completion Date

April 4, 2020

Study Completion Date

April 5, 2021

Conditions
Astrocytoma
Interventions
DRUG

Bevacizumab

Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.

DRUG

TVB-2640

TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.

Trial Locations (1)

78229

University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT03032484 - TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma | Biotech Hunter | Biotech Hunter